Dianosic
Dianosic is a biotech company dedicated to designing transformative intranasal solutions that improve patient quality of life and support rapid recovery. They focus on innovative drug delivery platforms for chronic rhinitis, rhinosinusitis, and intranasal bleeding, with ambitions to expand into central nervous system diseases. Their mission is to develop patient-centric, minimally invasive, long-term resorbable solutions that enhance treatment efficacy, safety, and adherence.
Industries
Nr. of Employees
small (1-50)
Products
Active resorbable intranasal scaffold — chronic rhinitis (ARIS‑R program)
An implantable, bioresorbable scaffold designed to deliver a low dose of corticosteroid locally in the nasal cavity for approximately six months to treat persistent moderate-to-severe allergic rhinitis.
Active resorbable intranasal scaffold — chronic rhinosinusitis (ARIS‑S program)
An implantable, bioresorbable scaffold intended to provide local corticosteroid delivery for up to 12 months to manage symptoms of chronic rhinosinusitis in adults.
Nose‑to‑brain intranasal delivery program (NTB)
An R&D program exploring intranasal formulations and delivery concepts intended to deliver therapeutic agents to the central nervous system via nasal routes, leveraging drug‑eluting polymer scaffold know‑how.
Asymmetric intranasal inflatable balloon for epistaxis management (intranasal tamponade device)
A minimally invasive asymmetric intranasal inflatable device designed to control anterior and posterior nasal bleeding with features for atraumatic insertion, an anti‑migration disk, a hollow breathing channel and deployment markers.
Active resorbable intranasal scaffold — chronic rhinitis (ARIS‑R program)
An implantable, bioresorbable scaffold designed to deliver a low dose of corticosteroid locally in the nasal cavity for approximately six months to treat persistent moderate-to-severe allergic rhinitis.
Active resorbable intranasal scaffold — chronic rhinosinusitis (ARIS‑S program)
An implantable, bioresorbable scaffold intended to provide local corticosteroid delivery for up to 12 months to manage symptoms of chronic rhinosinusitis in adults.
Nose‑to‑brain intranasal delivery program (NTB)
An R&D program exploring intranasal formulations and delivery concepts intended to deliver therapeutic agents to the central nervous system via nasal routes, leveraging drug‑eluting polymer scaffold know‑how.
Asymmetric intranasal inflatable balloon for epistaxis management (intranasal tamponade device)
A minimally invasive asymmetric intranasal inflatable device designed to control anterior and posterior nasal bleeding with features for atraumatic insertion, an anti‑migration disk, a hollow breathing channel and deployment markers.
Services
Clinical education and training
Provision of procedural steps, instructional videos, webinars and an augmented‑reality mobile application to train healthcare professionals on device use and procedures.
Clinical case collection and peer forum
A clinician-facing forum and clinical case submission process to share real‑world cases, best practices and procedural feedback.
Clinical education and training
Provision of procedural steps, instructional videos, webinars and an augmented‑reality mobile application to train healthcare professionals on device use and procedures.
Clinical case collection and peer forum
A clinician-facing forum and clinical case submission process to share real‑world cases, best practices and procedural feedback.
Expertise Areas
- Intranasal drug delivery
- Implantable resorbable scaffold development
- Epistaxis (intranasal bleeding) device therapy
- Formulation development for sustained release
Key Technologies
- Drug‑eluting resorbable polymers
- Biodegradable polymer scaffolds
- Sustained‑release formulation
- Intranasal scaffold architecture